EBR Systems (EBR) investor relations material

Executive summary

• Achieved key Q2 2026 milestones, including FDA approval, premium reimbursement, and strong commercial momentum with 46 WISE implants, 17 new contracts, and 26 physicians trained, totaling 117 implants, 52 contracts, and 90 trained physicians.

• Commercial focus shifted to deeper utilization within existing accounts, with over half of activated accounts completing three or more implants.

• Major purchase agreements signed with HCA Healthcare, Advocate Health, and CHRISTUS Health.

• Addressed recent patient fatality as a known risk, not due to device malfunction, with proactive communication and no impact on business fundamentals.

• Positive demand and strong patient identification and scheduling projected for H2 2026.

Financial highlights

• Preliminary unaudited Q2 2026 revenue expected between US $2.50M and $2.60M, subject to closing adjustments.

• Initiated an AUD 150 million capital raise, with the final AUD 35 million tranche expected to close by 24 August 2026.

• Recent financing ensures full funding for the pathway to cash flow break-even and U.S. commercial scale-up.

Outlook and guidance

• Commercial execution strategy now emphasizes deeper account utilization over expanding new sites for sustainable adoption.

• No plans to slow rollout due to recent adverse events; enhanced training and communication emphasized.

• Broader Medicare coverage anticipated as CMS initiates National Coverage Determination process.